All In MedTech

Device Trial Radar · NCT01601301

Post-Market Study of the Ellipse PRECICE Intramedullary Limb Lengthening System

A Post-Market Prospective Evaluation of the Performance and Safety of the Ellipse PRECICE Intramedullary Limb Lengthening System

Last checked: Nov 20, 2026Latest source record: Feb 5, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

32

Actual

Start

Jul 2012

Primary completion

Jun 2018

Study completion Jun 2018

Sponsor

Lead sponsor
Ellipse Technologies, Inc.Not on our public-company list
Sponsor type
Industry
First posted
May 18, 2012

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to obtain post market performance and safety data of the Ellipse PRECICE Intramedullary Limb Lengthening System for subjects undergoing unilateral limb lengthening.

Conditions

  • Limb Length Discrepancy

Interventions

  • PRECICE SystemDevice

    Lenthening of either the tibia or femur with the PRECICE System.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Distraction Control: actual distraction rate vs. target distraction rateTime frame: Postoperatively, every 7-10 days up until the subject's distraction regimen is complete, an expected average of 33 days

Locations

6 sites in 1 country. Site status is shown where the registry gives one.

  • Loma Linda University

    Loma Linda, California

  • Nemours Children's Hospital

    Orlando, Florida

  • Paley Advanced Limb Lengthening Institute

    West Palm Beach, Florida

3 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.